Lotus Pharmaceuticals has received a patent pending notice from China’s Intellectual Property Office for Gliclazide-Controlled Release Tablets, a controlled release form of the hypoglycemic drug gliclazide that is aimed at type 2 diabetes. Lotus filed for the patent in 2008. According to Lotus, the SFDA has approved the company’s pre-clinical evaluation of the drug. More details...

Stock Symbol: (OTCBB: LTUS)